Clinical trial
Amisulpride in Schizophrenic Acute Phase Patients
NCT00436371 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00436371 |
|---|---|
| Title | Amisulpride in Schizophrenic Acute Phase Patients |
| Official title | The Use of Amisulpride in Schizophrenic Acute Phase Patients. |
| Acronym | ASAP |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | Amisulpride |
| Enrollment | 50 |
| Start date | May 1, 2005 |
| Primary completion | Nov 1, 2006 |
| First posted | Feb 19, 2007 |
| Last update posted | Sep 5, 2008 |
| Countries | Hong Kong |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: